Fig. 1 · Structure

Documents & Downloads

Altretamine

Cat. No. A10059 CAS 645-05-6
Altretamine is classified as an alkylating antineoplastic agent.This unique structure is believed to damage tumor cells through the production of the weakly alkylating species formaldehyde, a product of CYP450-mediated N-demethylation.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Altretamine impaired GPX4-associated phospholipid-hydroperoxide reduction in lysates from treated U-2932 cells. This functional assay supports a lipid-repair mechanism in this model, without establishing direct GPX4 binding or a purified-enzyme IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Altretamine Research Summary

This section summarizes 3 in vitro studies of Altretamine from 2 published references. In vitro models include lysates from human U-2932 diffuse large B-cell lymphoma cells; human U-2932 diffuse large B-cell lymphoma cells.

Altretamine In Vitro Studies

In U-2932 cells, 0.5 mM altretamine increased lipid ROS. A separate 1 mM treatment left reduced-glutathione levels similar to vehicle control, consistent with an effect downstream of GSH depletion. These readouts alone do not demonstrate ferroptotic cell death. [1]

In ovarian carcinoma E cells, hexamethylmelamine activity depended on exposure time: 0.1–10 µg/ml produced little change in thymidine uptake after 48 h, whereas 120 h exposure reduced uptake. Low-dose effects largely reversed after drug removal. The endpoint measures DNA synthesis, and the highest nominal concentration (100 µg/ml) was incompletely soluble. [2]

GPX4 lipid-hydroperoxide reduction in treated-cell lysates

Biochemical assay · Lysates from human U-2932 diffuse large B-cell lymphoma cells [1]

Lysates from altretamine-treated cells retained a PC-OOH signal, whereas untreated lysates reduced the substrate. No-lysate material supplied a substrate control. This supports impaired GPX4-associated lipid repair in this lysate assay; it does not establish direct binding or a purified-enzyme IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Residual phosphatidylcholine hydroperoxide after lysate incubationqualitative substrate reduction Residual PC-OOH signal with treated lysate; no residual signal with untreated lysate.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 mM altretamine (cell treatment, Figure 5B)
Exposure duration
Cell-treatment duration not specified in the acquired Figure 5B/caption or relevant main methods; lysate reaction: 30 min at 37°C.
Method
LC-MS quantification of PC-OOH after incubation with 200 µg cellular protein and reduced glutathione.
Reported limits
Treatment duration and panel-specific replicate count not specified in the acquired main text/figure. SI was not retrieved. Chemical supplier/purity not established in acquired scope.
Methods and source locations

Compound reported in the paper: Altretamine; Compound label in the paper: ALT

Evidence concerns the named compound in the reported experimental system; supplier, purity and Adooq lot equivalence are not established.

Figure 5B and caption; altretamine Results; GPX4 enzymatic activity assay

Residual phosphatidylcholine hydroperoxide after lysate incubation: LC-MS, [PC-OOH + H+] m/z = 790.5; no-lysate and untreated-lysate controls. — Figure 5B image/caption and Results; GPX4 assay methods

Lipid oxidation and glutathione response in U-2932 cells

Cell-based study · Human U-2932 diffuse large B-cell lymphoma cells [1]

Altretamine increased the lipid-ROS-positive population at 0.5 mM. At the separate 1 mM condition, reduced-glutathione levels were similar to DMSO control; sulfasalazine depleted GSH and increased lipid ROS. The linked pathway readouts were obtained at different concentrations and do not establish ferroptotic death by themselves.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fraction within the displayed lipid-ROS gatepercentage of gated cells DMSO 4.3%; altretamine 0.5 mM 42.5%. Sulfasalazine comparator: DMSO 4.4%; 1 mM sulfasalazine 38.5%.[1]
Reduced glutathione normalized to proteinqualitative comparison Altretamine 1 mM: similar to DMSO control; sulfasalazine 1 mM: lower than control.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Altretamine: 0.5 mM for lipid ROS; 1 mM for GSH. Sulfasalazine comparator: 1 mM.
Exposure duration
Panel-specific drug exposure duration not specified in acquired main text/figure.
Method
C11-BODIPY flow cytometry for lipid ROS; Ellman reagent for GSH.
Vehicle
DMSO control; concentration not specified for these panels.
Reported limits
SI not acquired; panel-specific exposure times and GSH replicate/error-bar definition not established. Do not substitute profiling or viability-assay conditions.
Methods and source locations

Compound reported in the paper: Altretamine; Compound label in the paper: ALT

Evidence concerns the named compound in the reported experimental system; supplier, purity and Adooq lot equivalence are not established.

Figure 5A,C and caption; altretamine Results; cell culture and lipid ROS methods

Fraction within the displayed lipid-ROS gate: C11-BODIPY flow cytometry; biological triplicates, representative result displayed. — Figure 5C image and caption; Analysis of lipid ROS generation

Reduced glutathione normalized to protein: Ellman reagent; exact bar heights and error semantics not extracted. — Figure 5A image/caption; altretamine Results

Exposure-time dependence and recovery in ovarian carcinoma E cells

Cell-based study · E cell line derived from human ovarian carcinoma [2]

HMM had little effect on thymidine uptake at 0.1–10 µg/ml after 48 h. After 120 h, uptake fell at 0.1 µg/ml and at 100 µg/ml. Recovery after drug removal was concentration dependent. These DNA-synthesis readouts are not an IC50 or a direct cell-death count. No PMM or HMPMM was detected in medium in a separate 24 h metabolism check, but the authors explicitly did not exclude low-level activation below detection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
[3H]thymidine uptake after 48 h, percentage of control% control ± s.e. Control 100 ± 7.8; HMM 0.1 µg/ml: 98 ± 5.4; 1 µg/ml: 99 ± 4.6; 10 µg/ml: 102 ± 5.0.[2]
[3H]thymidine uptake after 120 h and after subsequent 72 h drug-free recovery% control ± s.e. HMM 0.1 µg/ml: 62 ± 5.7 after treatment, 92 ± 8.9 after recovery; HMM 100 µg/ml: 51 ± 2.3 and 38 ± 2.9, respectively.[2]
Metabolite detection in medium after HMM exposurequalitative detection result After HMM 1 µg/ml for 24 h, no PMM or HMPMM detected at 10 ng/ml sensitivity; HMM did not disappear from the system.[2]

Literature-Reported Treatment Conditions

Treatment concentration
HMM 0.1, 1, 10 or 100 µg/ml; 100 µg/ml incompletely soluble.
Exposure duration
Time-course experiments: 1–120 h exposure; key tabulated endpoints 48 h and 120 h, with 72 h drug-free recovery after 120 h.
Method
Growth-medium exposure; drug-containing medium renewed every 24 h. [3H]thymidine added for the last 6 h of treatment or recovery.
Vehicle
Growth medium (MEM with 10% fetal calf serum and supplements).
Reported limits
Control is untreated growth-medium cells. n is reported as 10–20 samples per time and concentration, not a fixed biological-replicate count. Dissolved exposure at nominal 100 µg/ml is unknown.
Methods and source locations

Compound reported in the paper: Altretamine; Compound label in the paper: HMM

Evidence concerns the named compound in the reported experimental system; supplier, purity and Adooq lot equivalence are not established.

Pages 631–634: Methods, Tables I–II, Figure 1/caption, Figure 2/caption, Results/Discussion

[3H]thymidine uptake after 48 h, percentage of control: [3H]thymidine uptake; untreated controls. — Page 631, Table I and Methods

[3H]thymidine uptake after 120 h and after subsequent 72 h drug-free recovery: Dunnett test: P < 0.01 versus controls for 62 ± 5.7, 51 ± 2.3 and 38 ± 2.9; not marked significant for 92 ± 8.9. 10–20 samples per time/concentration. — Page 631, Table II and Methods

Metabolite detection in medium after HMM exposure: Gas chromatography of medium extracts; spiked HMM/PMM/TMM reference chromatogram. — Page 633, Figure 2/caption and Results; page 634 Discussion caveat

Specifications

Manufacturer Adooq Bioscience
CAS Number 645-05-6
Formula C9H18N6
Molecular Weight 210.3
Synonyms Hexalen
SMILES
CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 14 mg/mL (66.57 mM)
Water Insoluble
Ethanol 31 mg/mL (147.42 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Altretamine Research References

  1. [1] Woo JH, Shimoni Y, Yang WS, et al. Elucidating Compound Mechanism of Action by Network Perturbation Analysis. Cell (2015). PMID: 26186195 DOI: 10.1016/j.cell.2015.05.056 Source material
  2. [2] D'Incalci M, Erba E, Balconi G, et al. Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites. British journal of cancer (1980). PMID: 6770884 DOI: 10.1038/bjc.1980.106 Source material

Added to your cart

View Cart Checkout
Loading...